Masimo (MASI) stock surged Wednesday on its upbeat earnings and 2025 outlook, though one analyst cautioned cost reductions could squeeze future profitability.
During the fourth quarter, Masimo earned an adjusted $1.80 per share, soaring 44% year over year and beating expectations for $1.42 a share. The company also beat its own guidance for $1.35 to $1.50 per share.
↑ X NOW PLAYING How To Buy Stocks: Flat Base Chart PatternSales were in line with Masimo's preannouncement at $601 million, up about 9%.
In morning trades, Masimo stock jumped more than 8% to 184.46. Shares broke out of a flat base with a buy point at 180.97 on Jan. 30. Later, the stock fell as much 8% below that point, triggering a sell rule. Savvy investors are encouraged to cut their losses when a stock falls 7% to 8% below its entry.
Needham analyst Mike Matson retained his hold rating on Masimo stock despite the solid profit beat. He is concerned "that its aggressive cost reductions are likely to compromise future earnings growth."
For the current year, Masimo projects $1.5 billion to $1.53 billion in health care revenue, up 8% to 11%, excluding the impact of exchange rates. The company also calls for $5.10 to $5.40 earnings per share, minus some items.
Analysts currently project $1.52 billion and adjusted earnings of $5.25 per share. Matson noted Masimo will benefit from an extra week of sales in 2025. The company expects that to add 1% to revenue, he said in a report.
Though Masimo stock dropped into a sell zone earlier this month, shares still have a strong IBD Digital Relative Strength Rating of 90. This means Masimo stock has performed in the leading 10% of all stocks over the last 12 months.
Shares also bounded above their 50-day line on Wednesday, MarketSurge shows.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
YOU MAY ALSO LIKE:
Why IBD 50's Top Seed, Hims & Hers, Just Crashed On Its Upbeat Earnings
Tempus AI Reverses 192% Run. Why At Least One Analyst Remains A Believer.
Find Today's Best Growth Stocks To Watch With IBD 50
Looking For The Next Big Stock Market Winners? Start With These 3 Steps
Join IBD Live For Stock Ideas Each Morning Before The Open
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.